Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955532 | 0.88 | CA12 (0.70) | EPHX2RECQLEPHX1NPC1RAB9A | |
| SCHEMBL1425023 | 0.86 | EPHX2 (0.74) | EPHX2RECQLEPHX1NPC1RAB9A | |
| SCHEMBL4009460 | 0.86 | EPHX2 (0.78) | EPHX2 | |
| SCHEMBL3960592 | 0.85 | EPHX2 (0.72) | EPHX2RECQLEPHX1NPC1RAB9A | |
| SCHEMBL14433541 | 0.84 | EPHX2 (0.81) | EPHX2EPHX1 | |
| SCHEMBL13200773 | 0.83 | RECQL (0.73) | EPHX2RECQLEPHX1NPC1RAB9A | |
| SCHEMBL2716077 | 0.83 | EPHX2 (1.00) | EPHX2RECQL | |
| SCHEMBL11417263 | 0.81 | RAB9A (0.84) | EPHX2RECQLEPHX1NPC1RAB9A | |
| SCHEMBL1424917 | 0.81 | KMT2A (0.66) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL3958860 | 0.79 | EPHX2 (0.76) | EPHX2RECQLEPHX1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140836-B1 | AMIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20040092528-A1 | Agent for modulating excitatory synaptic transmission comprising a compound having alpha7 nicotinic acetylcholine receptor activation property | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | US | disclosed |
| US-6710043-B1 | POSSESS THE POTENTIATION OF THE CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20040014745-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1315494-A1 | AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-04 | — | — | EP | disclosed |
| EP-1235575-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002020016-A1 | AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA α7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO, LTD (JP) | 2002-03-14 | — | — | WO | disclosed |
| WO-2000072834-A9 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000072834-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014745-A1 | Amide compounds | CHRM1, CHRM2, CHRNE | EPHX2 328/4885RECQL 781/4885EPHX1 869/4885 |
| US-20040092528-A1 | Agent for modulating excitatory synaptic transmission comprising a compound having alpha7 nicotinic acetylcholine receptor activation property | CHRNA7, CHRNA5, CHRNA10 | EPHX2 1280/4885RECQL 2667/4885EPHX1 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.